Navigation Links
Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease
Date:6/15/2011

sults may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™ and Nutra-Apps™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

(Other trademarks belong to their respective owners)


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
4. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
5. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
6. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
7. Multiple Presentations Confirm Clinical Efficacy and High Rate of Patient Compliance Using Provent® Sleep Apnea Therapy to Treat Obstructive Sleep Apnea
8. Dry Eye Therapy Utilizing Cationic Novasorb® Technology Available Soon From OCuSOFT®
9. Accuray Successfully Completes Acquisition of TomoTherapy
10. Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
11. TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... DUBLIN , July 27, 2015 /PRNewswire/ ... has announced the addition of the ... Competitors And Opportunities: 2015-2020 Analysis And Forecasts" ... Comprehensive information and evaluation of the ... analysis of manufacturers, segmentation, product offerings, competitive ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
(Date:7/27/2015)... 2015 Syneron Medical Ltd. ... market leader in the aesthetic medical device marketplace, announced ... and Drug Safety (MFDS) regulatory clearance for the PicoWay® ... fulfill PicoWay orders from its Korean distribution partner, with ... the third quarter 2015. Amit Meridor, Chief ...
Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
... Ortho-McNeil to Continue Investigation of GDIR Agonists Under its ... ... 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today ... discovered by Arena and being investigated,for the treatment of type ...
... Phase 2 Program to Provide Initial Proof-of-Concept Data ... ... 7 VIA Pharmaceuticals,(Nasdaq: VIAP ), a biotechnology company focused ... today that,it has enrolled the first patient in its Phase 2 ...
Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 2VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 3VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 5
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth ... can incur a lot of stress, pain, discomfort and embarrassment, which is why they ... treatment reaps the benefits of implants with the cost savings of dentures for anyone ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... water brands also made the organization’s list. As its name clearly indicates, 10 Best ... Here is a description of the top three brands, along with a listing of ...
(Date:7/27/2015)... ... ... In a creative effort to provide clear information about the process of ... Dove Tree in Lubbock has shared a new infographic to illustrate the process. The ... the nationally recognized collegiate program and traditional adult program at The Ranch at Dove ...
(Date:7/27/2015)... ... July 27, 2015 , ... The new ... diagnostics applications is rapidly increasing and is driven by focused research of pharmaceutical ... increasingly being evaluated for use in bio implants. MWCNTs are used in the ...
(Date:7/27/2015)... ... July 27, 2015 , ... SupplyLogic, a marketing execution ... on its newly redesigned company Website. In the blog, Founder and CEO Kevin Sherlock ... popular comedian: "Comedian George Wallace always asks: ‘Why is it the closer you get ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2
... and relationships have helped many children reduce their levels of ... in August 2005, according to a new study. A second ... in the aftermath of the storm. The studies appear ... July/August 2010 issue of the journal Child Development . ...
... who survived the 2004 tsunami and ongoing civil war there ... to the youths, psychological health, but also daily stressors like ... after the disasters. The studies appear in a special ... of the journal Child Development . The first ...
... University of Texas MD Anderson Cancer Center remains the leading hospital ... according to the annual "Best Hospitals" survey published by U.S. News ... last nine years that MD Anderson has ranked number one in ... has been ranked one of the top two cancer hospitals in ...
... milk be avoided in the early months of an infant,s ... until baby starts eating solid food. But new research from ... cow,s milk in the first 15 days of life may ... Prof. Yitzhak Katz of Tel Aviv University,s Department of Pediatrics, ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, July 14 ... helps people drop pounds but does so with few side ... fighting the obesity epidemic, lorcaserin is a new type of ... associated with feelings of well-being and feeling full, and does ...
... HealthDay Reporter , WEDNESDAY, July 14 (HealthDay News) ... for Alzheimer,s disease for the first time in 25 years ... key change would put more focus on the various stages ... convened by the U.S. National Institute on Aging and the ...
Cached Medicine News:Health News:Hurricane Katrina's effects on children: Resilience and gender 2Health News:Sri Lankan children affected by war, tsunami, daily stressors 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 3Health News:Cow's milk does a baby good 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 3Health News:New Criteria for Alzheimer's Diagnosis Proposed 2Health News:New Criteria for Alzheimer's Diagnosis Proposed 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: